Series A investors Pfizer Venture Investments and Roche Venture Fund have returned for a $10m round three years later.
US-based protein analysis technology developer Biodesy has completed a $10m series B round featuring pharmaceutical firms Pfizer and Roche.
The corporates, which participated through respective units Pfizer Venture Investments and Roche Venture Fund, were joined by venture capital firm 5AM Ventures. The series B investors had previously combined to supply $15m in series A funding for Biodesy in 2013.
Biodesy has developed a device called Biodesy Delta System to help pharmaceutical researchers track and analyse conformational change as they…
